Nuffield Council Gives Green Light to the Prevention of Inherited Mitochondrial Disease
By Antony Blackburn-Starza,
BioNews
| 06. 12. 2012
The Nuffield Council on Bioethics has published an ethical review of
new techniques which aim to prevent the transmission of faulty mtDNA
from mother to child. The report concludes that such techniques are
ethically permissible, provided that further research establishes their
safety.
The Council said the benefits of children being born free of mitochondrial
disorders outweigh the ethical concerns raised over the potential use
of the techniques. It also highlighted the benefits of women carrying mutated mtDNA being able to have children who are genetically related to them, and ensuring that subsequent generations are also free from mitochondrial disorders.
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...
